| HOME >> BIOLOGY >> TECHNOLOGY |
7.3 Average Cost of Therapy
7.4 Usage Patterns
7.4.1 Diseased Population
7.4.2 Treatment Seeking Population
7.4.3 Diagnosis Population
7.4.4 Prescription Population
7.4.5 Therapeutic Usage Patterns
7.5 Product Analysis
7.5.1 Naglazyme
7.5.1.1 Sales of Naglazyme
8 The US Orphan Diseases Therapeutics Market
8.1 Market Overview
8.2 Market Forecasts
8.3 Usage Patterns
8.3.1 Diseased Population
8.3.2 Treatment Seeking Population
8.3.3 Diagnosis Population
8.3.4 Prescription Population
8.3.5 Therapeutic Usage Patterns
9 Europe Orphan Diseases Therapeutics Market
9.1 Market Overview
9.2 Market Forecasts
9.3 Usage Patterns
9.3.1 Diseased Population
9.3.2 Treatment Seeking Population
9.3.3 Diagnosis Population
9.3.4 Prescription Population
9.3.5 Therapeutic Usage Patterns
10 Japan Orphan Diseases Therapeutics Market
10.1 Market Overview
10.2 Market Forecasts
10.3 Usage Patterns
10.3.1 Diseased Population
10.3.2 Treatment Seeking Population
10.3.3 Diagnosis Population
10.3.4 Prescription Population
10.3.5 Therapeutic Usage Patterns
11 Global Orphan Diseases Therapeutics Market: Competitive Landscape
11.1 Overview
11.2 Competitor Profiling
11.2.1 Genzyme Corporation
11.2.1.1 Strengths - Broad Product Base and Orphan Drug Status Strengthens Company's positioning
11.2.1.2 Cerezyme
11.2.1.3 Fabrazyme
11.2.2 Celgene Corporation
11.2.2.1 Strengths - Orphan Drugs Driving Revenues in a Competition Free Environment
11.2.3 Actelion Pharmaceuticals
11.2.4 Shire Phar
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |